Skye Bioscience Inc expected to post a loss of 25 cents a share - Earnings Preview

Skye Bioscience

03/08/2026 12:12

Skye Bioscience Inc SKYE.OQ SKYE.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Skye Bioscience Inc is for a loss of 25 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Skye Bioscience Inc is $5.00, about 779.5% above its last closing price of $0.57
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.34
-0.31
-0.32
Missed
-3.5
Dec. 31 2026
-0.33
-0.30
-0.36
Missed
-21.4
Sep. 30 2025
-0.31
-0.33
-0.32
Beat
3.8​
Jun. 30 2025
-0.32
-0.31
-2.69
Missed
-763.8
​​Mar. 31 2025
-0.29
-0.29
-0.28
Beat
2.4
Dec. 31 2024
-0.27
-0.28
-0.24
Beat
15.5​
Sep. 30 2024
-0.25
-0.25
-0.10
Beat
60.1
Jun. 30 2024
-0.21
-0.19
-0.20
Missed
-2.6
This summary was machine generated August 3 at 11:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)